SWITCH: A randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer

European Urology

Volumn 68, Issue 5, 2015, Pages 837-847

  Eichelberg, Christian ^a   Vervenne, Walter L ^b   De Santis, Maria ^c   Fischer Von Weikersthal, Ludwig ^d   Goebell, Peter J ^e   Lerchenmüller, Christian ^f   Zimmermann, Uwe ^g   Bos, Monique M E M ^h   Freier, Werner ⁱ   Schirrmacher Memmel, Silke ^j   Staehler, Michael ^k   Pahernik, Sascha ^l   Los, Maartje ^m   Schenck, Marcus ⁿ   Flörcken, Anne ^o   Van Arkel, Cornelis ^p   Hauswald, Kirsten ^q   Indorf, Martin ^q   Gottstein, Dana ^r   Michel, Maurice S ^s  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DEVENTER HOSPITAL   (Netherlands)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

^d Klinikum Amberg   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f Onkologisches Zentrum Münster   (Germany)

^g UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^h REINIER DE GRAAF HOSPITAL   (Netherlands)

ⁱ Onkologische Praxis   (Germany)

^j KLINIKUM FULDA   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^m ST ANTONIUS HOSPITAL   (Netherlands)

ⁿ UNIVERSITY HOSPITAL ESSEN   (Germany)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^p SLINGELAND HOSPITAL   (Netherlands)

^q iOMEDICO   (Germany)

^r ICRC Weyer GmbH   (Germany)

^s UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Renal cell carcinoma; Sequential therapy; Sorafenib; Sunitinib

Indexed keywords

SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY METASTASIS; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PYRROLES;

EID: 84942991426     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.04.017     Document Type: Article

References (44)

1. E.A. Singer, G.N. Gupta, D. Marchalik, and R. Srinivasan Evolving therapeutic targets in renal cell carcinoma Curr Opin Oncol 25 2013 273 280
2. R.J. Motzer, C. Porta, N.J. Vogelzang, and et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial Lancet Oncol 15 2014 286 296
3. C. Porta, G. Tortora, C. Linassier, and et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement Med Oncol 29 2012 1896 1907
4. S. Oudard, and R.T. Elaidi Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit Cancer Treat Rev 38 2012 981 987
5. D.B. Mendel, A.D. Laird, X. Xin, and et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337
6. S.M. Wilhelm, C. Carter, L. Tang, and et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
7. B. Escudier, T. Eisen, W.M. Stadler, and et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
8. T.E. Hutson, B. Escudier, E. Esteban, and et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 32 2014 760 767
9. B. Ljungberg, K. Bensalah, A. Bex, and et al. Guidelines on renal cell carcinoma European Association of Urology 2014
10. R.J. Motzer, D. Nosov, T. Eisen, and et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial J Clin Oncol 31 2013 3791 3799
11. B.I. Rini, B. Escudier, P. Tomczak, and et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
12. T. Buchler, T. Pavlik, Z. Bortlicek, and et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma Med Oncol 29 2012 3321 3324
13. N. Calvani, F. Morelli, S. Leo, and et al. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol 29 2012 1908 1913
14. C. Eichelberg, R. Heuer, F.K. Chun, and et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis Eur Urol 54 2008 1373 1378
15. C. Porta, P. Procopio, G. Cartenì, and et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 2011 E250 E257
16. F. Stenner, R. Chastonay, H. Liewen, and et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma Oncology 82 2012 333 340
17. C. Porta, G. Procopio, G. Carteni, and et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases Presentation at the German Cancer Congress (DKK) 2010 abstr PO119
18. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
19. C. Eichelberg, P.J. Goebell, W.L. Vervenne, and et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer Ann Oncol 25 Suppl 4 2014 835P
20. J.E. Gschwend, A. Beeker, M. De Santis, and et al. Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study) J Clin Oncol 31 Suppl 2013 TPS4591
21. T.E. Hutson, V. Lesovoy, S. Al-Shukri, and et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial Lancet Oncol 14 2013 1287 1294
22. R.J. Motzer, T.E. Hutson, P. Tomczak, and et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
23. R.J. Motzer, T.E. Hutson, D. Cella, and et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722 731
24. N. Alimohamed, J.L. Lee, S. Srinivas, and et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma Clin Genitourin Cancer 12 2014 e127 e131
25. R.J. Motzer, C.H. Barrios, T.M. Kim, and et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma J Clin Oncol 32 2014 2765 2772
26. C.P. Filson, B.G. Redman, R.L. Dunn, and D.C. Miller Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma Urology 77 2011 825 830
27. C. Porta, C. Paglino, I. Imarisio, and et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy BMC Cancer 11 2011 105
28. A. Ambring, I. Bjorholt, E. Lesen, U. Stierner, and A. Oden Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study Med Oncol 30 2013 331 338
29. B. Escudier, C. Porta, P. Bono, and et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study J Clin Oncol 32 2014 1412 1418
30. N. Bhojani, C. Jeldres, J.J. Patard, and et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma Eur Urol 53 2008 917 930
31. T. Eisen, C.N. Sternberg, C. Robert, and et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies J Natl Cancer Inst 104 2012 93 113
32. T.E. Hutson, J. Bellmunt, C. Porta, and et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET Eur J Cancer 46 2010 2432 2440
33. G. Procopio, J. Bellmunt, J. Dutcher, and et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis Br J Cancer 108 2013 311 318
34. T.F. Chu, M.A. Rupnick, R. Kerlela, and et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019
35. G. Di Lorenzo, R. Autorino, G. Bruni, and et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Ann Oncol 20 2009 1535 1542
36. P.S. Hall, L.C. Harshman, S. Srinivas, and R.M. Witteles The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients JACC Heart Fail 1 2013 72 78
37. P. Ivanyi, and V. Grunwald Confusion of therapeutic approaches Dtsch Arztebl Int 111 2014 405
38. C.J. Richards, Y. Je, F.A. Schutz, and et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib J Clin Oncol 29 2011 3450 3456
39. R. Altena, E.G. de Vries, J.A. Gietema, P.J. Perik, and D.J. van Veldhuisen Cardiovascular toxicity caused by cancer treatment: strategies for early detection Lancet Oncol 10 2009 391 399
40. S.A. Jensen, P. Hasbak, J. Mortensen, and J.B. Sorensen Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle J Clin Oncol 28 2010 5280 5286
41. N.B. Haas, J. Manola, B. Ky, and et al. Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC) J Clin Oncol 30 Suppl 2012 4500
42. G. Procopio Role of sorafenib in renal cell carcinoma: focus on elderly patients Expert Rev Anticancer Ther 11 2011 1689 1692
43. G. Procopio, L. Derosa, A. Gernone, and et al. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting Future Oncol 10 2014 1741 1750
44. O. Derbel Miled, C. Dionne, C. Terret, and et al. Sorafenib and sunitinib for elderly patients with renal cell carcinoma J Geriatr Oncol 4 2013 255 261